Related Experiment Video

Updated: Aug 17, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

[A clinical study on cefteram pivoxil in pediatrics]

Y Satoh1, K Ishikawa, S Iwata

  • 1Department of Pediatrics, Ohta General Hospital.

The Japanese Journal of Antibiotics
|August 1, 1989
PubMed

Insights

Cefteram pivoxil demonstrated high efficacy in treating pediatric infections, with a 94.9% overall clinical response rate. This antibiotic also showed a high bacterial eradication rate and a favorable safety profile.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Antimicrobial Therapy

Context:

  • Pediatric infections pose a significant health challenge, necessitating effective and safe treatment options.
  • Cefteram pivoxil (CFTM-PI) is an antibiotic evaluated for its therapeutic potential in pediatric populations.
  • Understanding the clinical efficacy and safety of CFTM-PI is crucial for its appropriate use.

Purpose:

  • To evaluate the clinical efficacy of cefteram pivoxil in pediatric patients with various infections.
  • To assess the bacteriological eradication rates of CFTM-PI against common pediatric pathogens.
  • To determine the safety and tolerability profile of cefteram pivoxil in children.

Summary:

  • Clinical evaluations of cefteram pivoxil (CFTM-PI) in 39 pediatric patients showed an overall efficacy rate of 94.9% (16 excellent, 21 good, 1 fair, 1 poor).
  • Bacteriological assessment revealed high eradication rates: 94.1% for Gram-positive cocci (17 strains) and 90.9% for Gram-negative rods (22 strains).
  • Adverse events were infrequent (8.7%), including mild gastrointestinal issues and skin reactions; one case of eosinophilia was noted.

Impact:

  • The findings suggest cefteram pivoxil is a highly effective and safe therapeutic option for treating pediatric infections.
  • CFTM-PI's broad spectrum of activity and favorable safety profile support its consideration in pediatric infectious disease management.
  • This study contributes valuable data for clinicians and researchers regarding the use of CFTM-PI in pediatric care.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...